News & Updates

In individuals with obesity and moderate-to-severe pain due to knee osteoarthritis (OA), treatment with the GLP-1 RA* semaglutide led to significantly greater reductions in body weight and pain related to knee OA as opposed to placebo, findings from the STEP** 9 trial suggest.

In the phase II/III ENRICH trial, first-line (1L) ibrutinib with rituximab (IR) demonstrates superiority over rituximab plus chemotherapy (R-chemo; either R-CHOP* or bendamustine**-R) in older patients with previously untreated mantle cell lymphoma (MCL).